Matches in SemOpenAlex for { <https://semopenalex.org/work/W4304112818> ?p ?o ?g. }
- W4304112818 endingPage "1450" @default.
- W4304112818 startingPage "1441" @default.
- W4304112818 abstract "Standard treatment options for patients with stage IIA or stage IIB seminoma include either para-aortic and pelvic radiotherapy or three to four cycles of cisplatin-based combination chemotherapy. These options result in 3-year progression free survival rates of at least 90%, but bear risks for acute and late toxic effects, including secondary malignancies. We tested a novel approach combining de-escalated chemotherapy with de-escalated involved node radiotherapy, with the aim of reducing toxicity while preserving efficacy.In the single-arm, multicentre, phase 2 SAKK 01/10 trial, patients with stage IIA or IIB classic seminoma (either at primary diagnosis or at relapse during active surveillance for stage I) were enrolled at ten centres of the Swiss Group for Clinical Cancer Research and ten centres of the German Testicular Cancer Study Group. WHO performance status 0-2, age 18 years or older, and adequate bone marrow and kidney function were required for eligibility. Treatment comprised one cycle of carboplatin (area under the curve 7) followed by involved-node radiotherapy (30 Gy in 15 fractions for stage IIA disease and 36 Gy in 18 fractions for stage IIB disease). The primary endpoint was 3-year progression-free survival. Efficacy analyses were done on the full analysis set, which comprised all patients who signed the informed consent, were registered in the trial, initiated trial treatment, and met all medically relevant inclusion or exclusion criteria. Safety was assessed in all patients who were treated at least once with one of the trial treatments. The study is ongoing but no longer recruiting, and is registered with Clinicaltrials.gov, NCT01593241.Between Oct 18, 2012, and June 22, 2018, 120 patients were registered in the study. 116 patients were eligible and started treatment according to the study protocol (46 patients with stage IIA disease and 70 with stage IIB disease). After a median follow-up of 4·5 years (IQR 3·9-6·0), 3-year progression-free survival was 93·7% (90% CI 88·5-96·6). With a target progression-free survival of 95% at 3 years, the primary endpoint was not met. Acute treatment-related adverse events of any grade were noted in 58 (48%) of 116 patients, and grade 3 or 4 treatment-related adverse events occurred in the form of neutropenia in five (4%) patients, thrombocytopenia in three (3%) patients, and vomiting in one (1%) patient. No treatment-related deaths and no late treatment-related adverse events were reported. Serious adverse events were reported in five (4%) of 116 patients (one transient creatinine increase and four second primary tumours).Despite the fact that the primary endpoint was not met, we observed favourable 3-year progression-free survival with single-dose carboplatin area under the curve 7 and involved-node radiotherapy, with minimal toxic effects. Our findings might warrant discussion with patients about the SAKK 01/10 regimen as an alternative to standard-of-care treatment, but more research on this strategy is needed.Swiss State Secretariat for Education, Research and Innovation and Rising Tide Foundation for Clinical Cancer Research." @default.
- W4304112818 created "2022-10-11" @default.
- W4304112818 creator A5002259351 @default.
- W4304112818 creator A5004138772 @default.
- W4304112818 creator A5008587864 @default.
- W4304112818 creator A5009922782 @default.
- W4304112818 creator A5010990966 @default.
- W4304112818 creator A5011868198 @default.
- W4304112818 creator A5019298885 @default.
- W4304112818 creator A5030071814 @default.
- W4304112818 creator A5030372221 @default.
- W4304112818 creator A5042221345 @default.
- W4304112818 creator A5048850127 @default.
- W4304112818 creator A5050931392 @default.
- W4304112818 creator A5050974067 @default.
- W4304112818 creator A5051003180 @default.
- W4304112818 creator A5066701721 @default.
- W4304112818 creator A5072055620 @default.
- W4304112818 creator A5072369822 @default.
- W4304112818 creator A5082338484 @default.
- W4304112818 creator A5089969952 @default.
- W4304112818 date "2022-11-01" @default.
- W4304112818 modified "2023-10-05" @default.
- W4304112818 title "Single-dose carboplatin followed by involved-node radiotherapy for stage IIA and stage IIB seminoma (SAKK 01/10): a single-arm, multicentre, phase 2 trial" @default.
- W4304112818 cites W1550111394 @default.
- W4304112818 cites W1833467461 @default.
- W4304112818 cites W1986631450 @default.
- W4304112818 cites W2007988755 @default.
- W4304112818 cites W2033870127 @default.
- W4304112818 cites W2079405556 @default.
- W4304112818 cites W2096262742 @default.
- W4304112818 cites W2106614331 @default.
- W4304112818 cites W2111345124 @default.
- W4304112818 cites W2119160857 @default.
- W4304112818 cites W2130803751 @default.
- W4304112818 cites W2133050123 @default.
- W4304112818 cites W2140944538 @default.
- W4304112818 cites W2146342452 @default.
- W4304112818 cites W2146770164 @default.
- W4304112818 cites W2149953171 @default.
- W4304112818 cites W2152104760 @default.
- W4304112818 cites W2158551593 @default.
- W4304112818 cites W2160967394 @default.
- W4304112818 cites W2163695063 @default.
- W4304112818 cites W2164840905 @default.
- W4304112818 cites W2170763390 @default.
- W4304112818 cites W2315973725 @default.
- W4304112818 cites W2527896025 @default.
- W4304112818 cites W2559591136 @default.
- W4304112818 cites W2607430423 @default.
- W4304112818 cites W2736104174 @default.
- W4304112818 cites W2792836904 @default.
- W4304112818 cites W2865362922 @default.
- W4304112818 cites W2886615577 @default.
- W4304112818 cites W2945860161 @default.
- W4304112818 cites W2980139474 @default.
- W4304112818 cites W3092245021 @default.
- W4304112818 cites W3134870122 @default.
- W4304112818 cites W4212894151 @default.
- W4304112818 cites W4229053954 @default.
- W4304112818 cites W4280584614 @default.
- W4304112818 doi "https://doi.org/10.1016/s1470-2045(22)00564-2" @default.
- W4304112818 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36228644" @default.
- W4304112818 hasPublicationYear "2022" @default.
- W4304112818 type Work @default.
- W4304112818 citedByCount "13" @default.
- W4304112818 countsByYear W43041128182022 @default.
- W4304112818 countsByYear W43041128182023 @default.
- W4304112818 crossrefType "journal-article" @default.
- W4304112818 hasAuthorship W4304112818A5002259351 @default.
- W4304112818 hasAuthorship W4304112818A5004138772 @default.
- W4304112818 hasAuthorship W4304112818A5008587864 @default.
- W4304112818 hasAuthorship W4304112818A5009922782 @default.
- W4304112818 hasAuthorship W4304112818A5010990966 @default.
- W4304112818 hasAuthorship W4304112818A5011868198 @default.
- W4304112818 hasAuthorship W4304112818A5019298885 @default.
- W4304112818 hasAuthorship W4304112818A5030071814 @default.
- W4304112818 hasAuthorship W4304112818A5030372221 @default.
- W4304112818 hasAuthorship W4304112818A5042221345 @default.
- W4304112818 hasAuthorship W4304112818A5048850127 @default.
- W4304112818 hasAuthorship W4304112818A5050931392 @default.
- W4304112818 hasAuthorship W4304112818A5050974067 @default.
- W4304112818 hasAuthorship W4304112818A5051003180 @default.
- W4304112818 hasAuthorship W4304112818A5066701721 @default.
- W4304112818 hasAuthorship W4304112818A5072055620 @default.
- W4304112818 hasAuthorship W4304112818A5072369822 @default.
- W4304112818 hasAuthorship W4304112818A5082338484 @default.
- W4304112818 hasAuthorship W4304112818A5089969952 @default.
- W4304112818 hasConcept C126322002 @default.
- W4304112818 hasConcept C126894567 @default.
- W4304112818 hasConcept C141071460 @default.
- W4304112818 hasConcept C143998085 @default.
- W4304112818 hasConcept C146357865 @default.
- W4304112818 hasConcept C151730666 @default.
- W4304112818 hasConcept C203092338 @default.
- W4304112818 hasConcept C2776694085 @default.
- W4304112818 hasConcept C2778074268 @default.
- W4304112818 hasConcept C2778239845 @default.